Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
67.44
+0.32 (0.48%)
May 18, 2026, 4:00 PM EDT - Market closed
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $376.71M in the quarter ending March 31, 2026, with 42.23% growth. This brings the company's revenue in the last twelve months to $1.51B, up 39.12% year-over-year. In the year 2025, Halozyme Therapeutics had annual revenue of $1.40B with 37.55% growth.
Revenue (ttm)
$1.51B
Revenue Growth
+39.12%
P/S Ratio
5.30
Revenue / Employee
$3,566,095
Employees
423
Market Cap
8.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.40B | 381.29M | 37.55% |
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.20K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | 2.82M | 287.02% |
| Dec 31, 2006 | 981.75K | 854.54K | 671.76% |
| Dec 31, 2005 | 127.21K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bio-Techne | 1.21B |
| Krystal Biotech | 417.30M |
| ImmunityBio | 140.98M |
| Cytokinetics | 105.82M |
| Protagonist Therapeutics | 74.06M |
| Kymera Therapeutics | 51.48M |
| Praxis Precision Medicines | 7.46M |
| ABIVAX Société Anonyme | 5.37M |
HALO News
- 6 days ago - Halozyme price target lowered to $93 from $96 at Morgan Stanley - TheFly
- 7 days ago - Halozyme Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Halozyme Therapeutics Earnings release: Q1 2026 - Filings
- 7 days ago - Halozyme Therapeutics Quarterly report: Q1 2026 - Filings
- 7 days ago - Halozyme Therapeutics Slides: Q1 2026 - Filings
- 7 days ago - HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE - PRNewsWire
- 11 days ago - Halozyme announces global collaboration and license agreement with GSK - TheFly
- 11 days ago - Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets - PRNewsWire